Periscope Capital’s Moderna MRNA Stock Holding History

Periscope Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,000	Closed	-$207K	–	498
2023 Q3	$207K	Buy	+2,000	New	+$223K	0.02%	249

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Periscope Capital's MRNA Position: Q1 2022 in Review

Periscope Capital sold out of Moderna (MRNA) in Q1 2022, closing a stake of 826 shares — an estimated $210K sold.

Periscope Capital first reported a position in MRNA in Q4 2021 and held it in 1 quarter. The position peaked at $210K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Periscope Capital reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Periscope Capital sold 826 Moderna shares in Q1 2022, an estimated $210K.
Periscope Capital first reported a position in Moderna in Q4 2021 and held it in 1 quarter.
Periscope Capital's Moderna position peaked at $210K in Q4 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Periscope Capital's 13F filing for Q1 2022, filed 16 May 2022.